FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment ...

Acanthamoeba keratitis is a rare but blinding parasitic eye disease. Experts share how to avoid it and treat it.

The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...

Under the FDA-authorized expanded access (IND 176297), urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no ...

Valian joins Emmecell following a distinguished career at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of high-impact ophthalmic ...

What makes glaucoma especially dangerous is its lack of early symptoms. A doctor explains why screening matters.

Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable ...

Marjan Farid, M.D. brings world renown anterior segment clinical expertise and established the first Center of Excellence expansion site at the University of California, Irvine James Mazzo brings over ...

With high temperatures and very high UV levels at the Australian Open, BBC Sport looks at the effects of playing for hours outdoors.

If you were to listen to a day in the life of a veterinary ophthalmologist, you’d likely hear words and phrases you’ve never heard before. “A tubing system will be placed under your horse’s eyelid to ...

Emmecell, a clinical-stage biotechnology company, has appointed Ramin Valian as Chief Executive Officer (CEO).